Bajou Khalid, Maillard Catherine, Jost Maud, Lijnen Roger H, Gils Ann, Declerck Paul, Carmeliet Peter, Foidart Jean-Michel, Noel Agnès
Laboratory of Tumor and Development Biology, CRCE, University of Liège, Tour de Pathologie (B23), Sart Tilman, B-4000 Liège, Belgium.
Oncogene. 2004 Sep 9;23(41):6986-90. doi: 10.1038/sj.onc.1207859.
Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells (after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.
1型纤溶酶原激活物抑制剂(PAI-1)在肿瘤进展中起关键作用,并且被认为在血管生成过程中控制蛋白水解活性和细胞迁移。我们在此报告,宿主PAI-1在生理浓度下可促进体内肿瘤侵袭和血管生成。与之形成鲜明对比的是,当PAI-1通过宿主细胞(过表达PAI-1的转基因小鼠)或肿瘤细胞(用鼠PAI-1 cDNA转染后)以超生理水平产生时,可观察到肿瘤血管生成受到抑制。本研究首次在体内提供了PAI-1对肿瘤血管生成具有剂量依赖性效应的证据。非常有趣的是,发现肿瘤细胞产生的PAI-1即使在高浓度下也不能克服宿主中PAI-1的缺失,这强调了PAI-1细胞来源的重要性。